CClinicalTrials.gg
Sign In
TerminatedNCT04540120Updated Apr 13, 2023

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

A Phase 2 interventional study of dapansutrile capsules and placebo capsules in Covid19 and Cytokine Release Syndrome, sponsored by Olatec Therapeutics LLC. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Olatec Therapeutics LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated due to the treatment environment for COVID-19 evolving with the pervasiveness of vaccinations and other therapeutic modalities in mitigating against severe infection that has eliminated a viable patient population for study enrollment.

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 2 months ago, and no results have been posted to the registry.
Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with confirmed SARS-CoV-2 infection and moderate symptoms.

Coronavirus disease 2019 (COVID-19) is caused by infection from a new strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is characterized by fever, cough and shortness of breath, which in certain patients can lead to systemic organ failure and mortality.

The data show that SARS-CoV-2 activates the innate immune signaling sensor NLRP3. Activation of NLRP3 initiates the cytokine release syndrome (CRS), which includes the production of primary cytokine, IL-1, triggering an intense inflammatory response that is prevalent in symptomatic COVID-19 patients. When CRS advances further to a fulminant 'cytokine storm', the data show that respiratory distress syndrome and multiple-organ failure take place.

A specific inhibitor of NLRP3, dapansutrile may reduce or prevent the hyperinflammation associated with CRS by inhibiting the production of IL-1β early to arrest the progression to a severe 'cytokine storm.' The end result would be a reduction in the need for COVID-19 patients to receive intensive medical treatment, allowing for fewer hospitalizations, administration of mechanical ventilation and deaths.

Read the detailed description

This is a Phase 2, randomized, double-blind, placebo-controlled study evaluating dapansutrile versus placebo. Approximately 80 subjects randomized 1:1 (40 dapansutrile, 40 placebo) are planned to be enrolled.

At the Screening/Baseline/Day 1 Visit, subjects will provide informed consent, be screened for eligibility, and be randomized/enrolled into the study. Subjects will also receive the first dose of study drug at this visit once study eligibility has been confirmed, and the second dose of study drug will be taken approximately 12 hours after the first dose. Study drug will be continued twice daily (morning and evening doses) through Day 14.

The trial duration will be approximately 45 days for all subjects enrolled, with assessments as follows: Screening/Baseline/Day 1, Day 4 (±1 day), Day 8 (±1 day), Day 15 (±1 day), Day 29 (±3 days), and Day 45 (± 3 days). The Day 29 and Day 45 follow-up visits will be conducted virtually via the institution's telehealth process.

Each subject will be asked to maintain two paper diaries at home daily for the first 14 days: a dosing diary and a subject diary. The dosing diary will be used to record the number of capsules taken each morning and evening. The subject diary will be used to record temperature, oxygen levels, COVID-19 symptoms, and overall health (using the prior 24-hour period for parameters requiring subject recall). The set of questions used in the subject diary will also be administered to the subjects at the Screening/Baseline/Day 1 Visit (pre-dose), Day 15, Day 29, and Day 45 visits. Each subject will be provided a no-contact thermometer and a hand-held pulse oximeter at the Screening/Baseline/Day 1 Visit for home use.

At Day 29 and Day 45, additional assessments of safety and clinical activity will occur. The Day 29 and Day 45 follow-up visits will be conducted virtually via the sites' telehealth process.

02

Conditions studied

  • Covid19
  • Cytokine Release Syndrome

Keywords

  • NLRP3
  • Covid19
  • Cytokine Release Syndrome
  • Dapansutrile
03

In context

COVID-19

7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 49 is below the median of 100 across 4,098 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Olatec Therapeutics LLC is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male and female subjects ≥ 18 years of age;
  2. SARS-CoV-2-positive, confirmed by Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-authorized COVID-19 test ≤ 7 days prior to randomization;
  3. Less than or equal to 7 days from first symptom onset to randomization;

  4. Subjects with moderate COVID-19 consistent with the definition of "moderate" as set forth by the February 2021 FDA Guidance for Industry: COVID-19: Developing Drugs and Biological Products for Treatment or

    Prevention (FDA, 2021) who at the Screening/Baseline/Day 1 Visit:

    1. have felt feverish within the past 24 hours,
    2. have an SpO2 > 93% on room air at sea level when sitting, and
    3. meet at least one of the following criteria: i). Respiratory rate: ≥ 20 breaths/minute, when the subject is sitting, ii). SpO2: ≤ 96% on room air at sea level, when the subject is sitting, iii). Shortness of breath: with exertion, not requiring oxygen, or vi). Heart rate: ≥ 90 beats/minute, when the subject is sitting;

  5. If all the criteria in Inclusion 4c are met, subject must possess at least one of the following high-risk conditions known to have an underlying increased level of cytokine production; otherwise, at least two of these high-risk conditions must be met:

    1. 70 years or more of age,
    2. Obesity (BMI ≥ 30 kg/m2),
    3. Diabetes (type 1 or 2),
    4. Uncontrolled hypertension, defined as diastolic > 100 mm Hg and/or systolic > 150 mm Hg without any current anti-hypertensive medications. At the time of screening if the subject is on anti- hypertensive medication(s) and diastolic or systolic rates are elevated, subject may be enrolled after consultation with the Medical Monitor,
    5. Known respiratory disease (including asthma or chronic obstructive pulmonary disease [COPD]),
    6. Known heart failure (note: subjects with New York Heart Association Class IV congestive heart failure cannot be enrolled per Exclusion Criterion 4), or
    7. Known coronary disease;
  6. Plasma CRP level must be collected at Screening/Baseline/Day 1 Visit;
  7. Acceptable overall medical condition to be safely enrolled in and complete the study (with specific regard to cardiovascular, renal, and hepatic conditions) in the opinion of the Investigator;
  8. Ability to provide written, informed consent prior to initiation of any study- related procedures, and ability in the opinion of the Investigator to understand and comply with all the requirements of the study, which includes abstaining from the use of prohibited medications.
  9. Subject must present with at least moderate symptomatology, based on having symptoms in the prior 24 hours that were uncomfortable and interfered with daily activities or required treatment other than study drug and having at least one of the following symptoms: cough; fatigue; myalgia; diarrhea; vomiting; nausea; headache; sore throat; nasal congestion; rhinorrhea; loss of taste; loss of smell; fainting; or chills, shivering, and/or sweating.

Exclusion criteria

Exclusion Criteria:

  1. Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential, who:

    1. Are or intend to become pregnant (including use of fertility drugs) during the study;
    2. Are nursing (female subjects only);
    3. Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete.
  2. Evidence of pre-existing or new-onset organ failure;
  3. Evidence of moderate concurrent nervous system, renal, endocrine, or gastrointestinal disease, unrelated to COVID-19 as determined by the Investigator;
  4. Evidence of cardiovascular disease with significant arrhythmia, congestive heart failure (New York Heart Association Class IV), unstable angina, cor pulmonale, or symptomatic pericardial effusion, not related to COVID-19 as determined by the Investigator;
  5. Required use of vasoactive drug support;
  6. History of myocardial infarction in the 6 months prior to the Screening/Baseline/Day 1 Visit;
  7. Evidence of current liver disease, not related to COVID-19 as determined by the investigator;

  8. History or evidence of active tuberculosis (TB) infection at Screening/Baseline/Day 1 Visit or one of the risk factors for tuberculosis such as but not limited or exclusive to:

    1. History of any of the following: residence in a congregate setting (e.g., jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g., injection or non-injection), health-care workers with unprotected exposure to subjects who are at high risk of TB or subjects with TB disease before the identification and correct airborne precautions of the subject or
    2. Close contact (i.e., share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease within the last 12 months.
  9. History of or currently active primary or secondary immunodeficiency;
  10. Past or present requirement for oxygen (e.g., nasal cannula, proning, mechanical ventilation and/or supplemental oxygen).

  11. Use of any prohibited concomitant medications/therapies over the defined or planned use of any concomitant medications/therapies during the

    Treatment Period, including specifically:

    1. use of ibuprofen or diclofenac
    2. use of colchicine
    3. use of systemic steroids within 30 days of randomization
    4. use of janus kinase (JAK) inhibitors
    5. use of off-label agents (e.g., hydroxychloroquine, remdesivir, dexamethasone) and biologic and oral anti-cytokine agents (e.g., current treatment with adalimumab, infliximab, etanercept, golimumab, certolizumab pegol, tocilizumab, sarilumab, anakinra, canakinumab, rilonacept, baricitinib, tofacitinib, or upadacitinib);

    Note: During the treatment period a patient may meet the criteria for a treatment approved by the FDA specifically for COVID-19 (e.g. remdesivir). In this situation the investigator and medical monitor should confer and take the most appropriate decision for the patient. If possible, the preference would be for the patient to complete the 14 days of dosing before adding on the 2nd treatment. If that is not possible the preference would be for the patient to continue their 14 days on dapansutrile and complete all study related visits.

  12. Known history of renal impairment (e.g., calculated glomerular filtration rate [GFR] \< 45 mL/min);
  13. Evidence of malignant disease, or malignancies diagnosed within the previous 5 years (except for local basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured);
  14. History of infection or known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  15. Any other concomitant medical or psychiatric conditions, diseases, or prior surgeries that, in the opinion of the Investigator, would impair the subject from safely participating in the trial and/or completing protocol requirements;
  16. Individuals who have been in a chronic care facility in the past 30 days;
  17. Individuals who are incarcerated;
  18. Participation in any clinical trial and/or use of any investigational product within the immediate 30-day period prior to the Screening/Baseline//Day 1 Visit; or receipt prior to Screening/Baseline/Day 1 Visit or intending to receive during the trial a COVID-19 vaccination.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    dapansutrile capsules

    Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).

    Drug: dapansutrile capsules

  • Placebo comparator
    placebo capsules

    Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.

    Drug: placebo capsules

Interventions

  • Drugdapansutrile capsules

    Hard opaque capsules containing 250 mg of API.

    Also known as: OLT1177 capsules

  • Drugplacebo capsules

    Hard opaque capsules containing 0 mg of API.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with clinical deterioration

    Clinical deterioration is defined as having any COVID-19-related hospitalization after enrollment or both (1) worsening or persistence of shortness of breath and (2) oxygen saturation less than 92% on room air at sea level or need for supplemental oxygen to achieve oxygen saturation of 92% or greater.

    Time frame: Day 15

Secondary outcomes

  1. Proportion of subjects with complete resolution of fever symptoms and shortness of breath

    Complete resolution is defined as having a symptom described as "absent" on the subject diary with no return of the symptom before Day 45.

    Time frame: Day 8, Day 15, Day 29, Day 45

  2. Cumulative incidence of SAEs

    Evaluate the cumulative incidence of SAEs of dapansutrile relative to placebo

    Time frame: Day 45

  3. Cumulative incidence of Grade 3 and Grade 4 Adverse Events

    Evaluate the cumulative incidence of Grade 3 and Grade 4 Adverse Events of dapansutrile relative to placebo

    Time frame: Day 45

  4. Discontinuation or temporary suspension of participation

    Evaluate the cumulative incidence of discontinuation or temporary suspension (for any reason) of dapansutrile relative to placebo

    Time frame: Day 45

  5. Changes in white cell count

    Evaluate changes in white cell count of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  6. Changes in hemoglobin

    Evaluate changes in hemoglobin of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  7. Changes in platelets

    Evaluate changes in platelets of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  8. Changes in creatinine

    Evaluate changes in creatinine of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  9. Changes in glucose

    Evaluate changes in glucose of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  10. Changes in total bilirubin

    Evaluate changes in total bilirubin of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  11. Changes in ALT

    Evaluate changes in ALT of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  12. Changes in AST

    Evaluate changes in AST of dapansutrile relative to placebo over time

    Time frame: Day 8, Day 15

  13. Incidence of new infection that occurs during the study

    Evaluate changes in incidence of new infection that occurs during the study of dapansutrile relative to placebo

    Time frame: Day 8, Day 15

  14. Incidence of opportunistic infections

    Evaluate changes in incidence of opportunistic infections of dapansutrile relative to placebo

    Time frame: Day 8, Day 15

  15. Time to clinical improvement

    Time to clinical improvement in fever symptoms and shortness of breath

    Time frame: Baseline/Day 1 to Day 15

  16. Time to sustained absence of fever

    Time to sustained absence of fever, defined as at least 2 days since last temperature measurement of ≥ 38˚C (100.4°F)

    Time frame: Baseline/Day 1 to Day 15

  17. Clinical improvement in symptoms relevant to COVID 19

    Proportion of subjects who experience clinical improvement in symptoms relevant to COVID 19 (e.g., cough, diarrhea, vomiting)

    Time frame: Day 15

  18. Incidence of hospitalization, supplemental oxygen, mechanical ventilation, or death before Day 15

    Incidence of subjects meeting the composite endpoint of subjects requiring hospitalization (hospitalization is defined as ≥ 24 hours of acute care), supplemental oxygen, mechanical ventilation, or who die

    Time frame: Day 15

  19. Duration of hospitalization, supplemental oxygen or mechanical ventilation before Day 15

    Duration of incidences of subjects meeting the composite endpoint of subjects requiring hospitalization (hospitalization is defined as ≥ 24 hours of acute care), supplemental oxygen or mechanical ventilation

    Time frame: Day 15

  20. Clinical improvement in symptoms

    Proportion of subjects who experience clinical improvement in symptoms by Day 15, defined as a reduction of two or more points on the WHO Ordinal Scale for Clinical Improvement (lowest score between Baseline Visit/Day 1 and Day 15)

    Time frame: Baseline/Day 1 to Day 15

  21. Improvement in oxygenation

    Improvement in oxygenation over the course of the study and maintenance of this effect

    Time frame: Baseline/Day 1 to Day 15

  22. Change in ALT

    Assess and compare change from Baseline in AST

    Time frame: Baseline/Day 1 to Day 15

  23. Change in AST

    Assess and compare change from Baseline in AST

    Time frame: Baseline/Day 1 to Day 15

  24. Change in blood glucose

    Assess and compare change from Baseline in blood glucose

    Time frame: Baseline/Day 1 to Day 15

  25. Change in Erythrocyte Sedimentation Rate (ESR)

    Assess and compare change from Baseline in Erythrocyte Sedimentation Rate (ESR)

    Time frame: Baseline/Day 1 to Day 15

  26. Change in Hemoglobin A1c (HbA1C)

    Assess and compare change from Baseline in Hemoglobin A1c (HbA1C)

    Time frame: Baseline/Day 1 to Day 15

  27. Change in Lactate dehydrogenase (LDH)

    Assess and compare change from Baseline in Lactate dehydrogenase (LDH)

    Time frame: Baseline/Day 1 to Day 15

  28. Change in Lymphocyte, Absolute count

    Assess and compare change from Baseline in Lymphocyte, Absolute count

    Time frame: Baseline/Day 1 to Day 15

  29. Change in Monocyte, Absolute count

    Assess and compare change from Baseline in Monocyte, Absolute count

    Time frame: Baseline/Day 1 to Day 15

  30. Change in Neutrophils, Absolute count

    Assess and compare change from Baseline in Neutrophils, Absolute count

    Time frame: Baseline/Day 1 to Day 15

  31. Change in Eosinophil, Absolute count

    Assess and compare change from Baseline in Eosinophil, Absolute count

    Time frame: Baseline/Day 1 to Day 15

  32. Change in CRP

    Assess and compare change from Baseline in CRP

    Time frame: Baseline/Day 1 to Day 15

  33. Change in D-Dimer

    Assess and compare change from Baseline in D-Dimer

    Time frame: Baseline/Day 1 to Day 15

  34. Change in Ferritin

    Assess and compare change from Baseline in Ferritin

    Time frame: Baseline/Day 1 to Day 15

  35. Change in Fibrinogen

    Assess and compare change from Baseline in Fibrinogen

    Time frame: Baseline/Day 1 to Day 15

  36. Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)

    Assess and compare change from Baseline in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)

    Time frame: Baseline/Day 1 to Day 15

  37. Change in IL-1β

    Assess and compare change from Baseline in IL-1β

    Time frame: Baseline/Day 1 to Day 15

  38. Change in IL-6

    Assess and compare change from Baseline in IL-6

    Time frame: Baseline/Day 1 to Day 15

  39. Change in IL-18

    Assess and compare change from Baseline in IL-18

    Time frame: Baseline/Day 1 to Day 15

  40. Change in granulocyte colony-stimulating factor (G-CSF)

    Assess and compare change from Baseline in granulocyte colony-stimulating factor (G-CSF)

    Time frame: Baseline/Day 1 to Day 15

  41. Change in interferon-γ-induced protein 10 (IP-10)

    Assess and compare change from Baseline in interferon-γ-induced protein 10 (IP-10)

    Time frame: Baseline/Day 1 to Day 15

  42. Change in C3a

    Assess and compare change from Baseline in C3a

    Time frame: Baseline/Day 1 to Day 15

07

Study locations

10 sites
  • C&R Research Services USA
    Coral Gables, Florida 33134, United States
  • Invesclinic U.S. LLC
    Fort Lauderdale, Florida 33308, United States
  • Inpatient Research Clinic, LLC
    Hialeah, Florida 33013, United States
  • Sunrise Research Institute
    Sunrise, Florida 33325, United States
  • Las Vegas Medical Research, LLC
    Las Vegas, Nevada 89113, United States
  • PanAmerican Clinical Research LLC
    Brownsville, Texas 78520, United States
  • J & S Studies, Inc.
    College Station, Texas 77645, United States
  • C&R Research Services USA
    Houston, Texas 77023, United States
  • Texas Research Alliance LLC
    McAllen, Texas 78503, United States
  • University Hospital Basel
    Basel, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04540120
Lead sponsor
Olatec Therapeutics LLC
Collaborators
CTI Clinical Trial and Consulting Services
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Sep 24, 2020
Primary completion
Jul 28, 2022
Completion
Jul 28, 2022
Last update
Apr 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Olatec Therapeutics LLC

Start the discussion